New York Times (10.25.2013)
All 15 members of the US Food and Drug Administration’s (FDA) panel of virus experts voted unanimously to recommend approval of drug manufacturer Gilead’s pill sofosbuvir, which treats several forms of hepatitis C virus (HCV). While not required to follow the panel’s recommendations, the FDA often does. Currently available HCV treatments can take up to a year of therapy and cure only three out of four patients. When taken daily, sofosbuvir can cure up to 90 percent of individuals infected with the most common form of HCV in just 12 weeks. The FDA is expected to make a decision on the drug by December 8.